Hodder et al Disclosures Dr Steven Kesten (Corporate Department Medical Affairs. Ingelheim, Germany), Dr Shailendra Menjoge (Statistics and Data Management. Ridgeﬁeld, Connecticut, USA), and Klaus Viel (National Medicine. Ingelheim, Germany) are employees of Boehringer Ingelheim. Dr Rick Hodder is member of Scien- tiﬁc Advisory Boards established by Boehringer Ingelheim and Pﬁzer, has been speaker on scientiﬁc symposia sponsored by Boehringer Ingelheim and Pﬁzer, and has received grants from Boehringer Ingelheim to conduct clinical research trials. Abbreviations AUC, area under the curve; BDI, baseline dyspnea index; FVC, forced vital capacity; FEV , forced expiratory volume 1 in 1 second; ICS, inhaled corticosteroids; TDI, transition dys- pnea index; SGRQ, St. George Respiratory Questionnaire. References Aaron SD, Vandemheen KL, Fergusson D, et al, for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. 2007. Tiotropium in combination with placebo, salmeterol, or ﬂuticasone- salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med, 146:545–55. Alsaeedi A, Sin DD, McAlister FA. 2002. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of rand- omized placebo-controlled trials. Am J Med, vol. 113, no. 1:59–65. Barnes PJ. 2000. Inhaled corticosteroids are not beneﬁcial in chronic obstruc- tive pulmonary disease. Am J Respir Crit Care Med, 161:342–344. Barnes P. 2004. The role of anticholinergics in chronic obstructive pulmo- nary disease. Am J Med, 117:24S–32S. Barnes P, Adcock I, Ito K. 2005. Histone acetylation and deacetylation: importance in inﬂammatory lung diseases. Eur Respir J, 25:552–63. Barnes P, Ito K, Adcock I. 2004. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet, 363:731–3. Bourbeau J, Rouleau M, Boucher S. 1998. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax, 53:477–82. Brusasco V, Hodder R, Miravitlles M, et al. 2003. Health outcomes in a 6-month placebo-controlled trial of once daily tiotropium com- pared with twice daily salmeterol in patients with COPD. Thorax, 58:399–404. Burge P, Calverley P, Jones PW, et al. 2000. Randomised, double blind, placebo controlled study of ﬂuticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ, 320:1297–303. Calverley PM. 2000. Inhaled corticosteroids are beneﬁcial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:341–2. Calverley PM, Boonsawat W, Cseke Z, et al. 2003a. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912–19. Calverley PM, Pauwels R, Vestbo J, et al 2003b. Combined salmeterol and ﬂuticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361:449–56. Calverley P, Anderson J, Celli B, et al. 2007. Salmeterol and ﬂuticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775–89. Cazzola M, Centanni S, Santus P, et al. 2004a. The functional impact of adding salmeterol to tiotropium in patients with stable COPD. Respir Med, 98:1214–21. 166 Cazzola M, Donner C, Matera M. 1999. Long-acting β agonists and 2 theophyllines in stable chronic obstructive pulmonary disease. Thorax, 54:730–6. Cazzola M, Marco F, Santus P, et al. 2004b. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pul Pharmacol Ther, 17:35–9. Cazzola M, Spina D, Matera M. 1997. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pul Pharmacol Ther, 10:129–44. Culpitt SV, Rogers DF, Shah P, et al 2003. Impaired inhibition by dexam- ethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:24–31. Disse B, Speck GA, Rominger KL, et al. 1999. Tiotropium (Spiriva): mechanistical considerations and clinical proﬁle in obstructive lung disease. Life Sci, 64:457–64. Donaldson GC, Seemungal TAR, Bhowmik A, et al. 2002. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57:847–52. Donohue JF, Menjoge S, Kesten S. 2003. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med, 97:1014–20. Donohue J, Van Noord J, Bateman E, et al 2002. A 6-monthplacebo-control- led study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest, 122:47–55. Douglas N, Sudlow A, Julia-Serda G, et al. 1979. Effect of an inhaled atropine-like agent on normal airway function. J Appl Physiol, 46:256–62. GINA 1995. Global Initiative for Asthma (GINA). Global Strategy for asthma management and prevention. NHLBI/WHO Workshop Report. National Institutes of Health, National Heart Lung and Blood Institute. NIH Publication No.95; 3659. Gross NJ, Co E, Skorodin MS. 1989. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest, 96:984–7. Gross N. 2004. Tiotropium bromide. Chest, 126:1946–53. Gross N, Skorodin M. 1984. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med, 311:421–5. Hattotuwa K, Gizycki M, Ansari T, et al. 2002. The effects of inhaled ﬂuticasone on airway inﬂammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:1592–6. Jones PW, Quirk FH, Baveystock CM. 1991. The St George’s Respiratory Questionnaire. Respir Med, 85(Suppl B):25–31. Kanner RE, Anthonisen NR, Connett JE. 2001. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med, 164:358–64. Leigh R, Pizzichini M, Morris M, et al. 2006. Stable COPD: predicting beneﬁt from high-dose inhaled corticosteroid treatment. Eur Respir J, 27:964–71. Littner MR, Ilowite JS, Tashkin DP, et al 2000. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstruc- tive pulmonary disease. Am J Respir Crit Care Med, 161:1136–42. Lung Health Study Research Group. 2000. Effects of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 343:1902–9. Maesen FP, Smeets JJ, Sledsens TJ, et al. 1995. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J, 8:1506–13. Mahler DA, Weinberg DH, Wells CK, et al. 1984. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest, 85:751–58. Mahler DA, Wire P, Horstman D, et al. 2002. Effectiveness of ﬂuticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1668:1084–91. Morris JF, Koski A, Temple WP, et al. 1988. Fifteen-year interval spiromet- ric evaluation of the Oregon predictive equations. Chest, 93:123–7. International Journal of COPD 2007:2(2)